Elanco提供了2025全年的财务指引，具体如下： - 预计全年收入为44.45亿美元至45.1亿美元，低于市场预期的45.33亿美元。 - 调整后每股收益预计为0.80美元至0.86美元，低于市场预期的0.90美元。 公司预计，由于外汇汇率的不利影响，将对收入带来约1.1亿美元的逆风。剔除这些不利影响后，公司仍预计收入将加速增长至中个位数。 公司预计，由于全球创新产品组合的推出，运营费用将按年增加约6%。全年调整后的息税折旧及摊销前收益（EBITDA）预计将包括约4500万美元的不利外汇影响。 "我们专注于加速2025年有机的固定汇率收入增长，并继续努力提高我们的盈利潜力和杠杆状况，"Elanco动物健康的执行副总裁兼首席财务官Todd Young表示，"在应对动态的宏观经济环境时，我们对2025年展望的底层驱动因素仍充满信心。唯一的调整是根据本月早些时候的汇率计算的增量货币逆风。我们预计2025年调整后的EBITDA将较历史节奏更加偏向下半年，因为强势美元和我们在全球创新产品推出的战略投资会推动创新收入贡献的增加。"

以上内容来自Benzinga Earnings专栏，原文如下：

Elanco is providing financial guidance for the full year 2025, summarized in the following table, subject to the assumptions described below:

The company anticipates a headwind to revenue of approximately $110 million from the unfavorable impact of foreign exchange rates compared to prior year and since the November earnings call. Excluding the unfavorable impact of foreign exchange rates and the aqua divestiture, the company continues to expect revenue growth to accelerate to mid-single digits.

The company expects operating expenses to increase approximately 6% year over year in constant currency with strategic investment in the global launches of the innovation portfolio. Full year adjusted EBITDA includes an anticipated foreign exchange rate impact of approximately $45 million compared to prior year and since the November earnings call.

"We are focused on accelerating organic constant currency revenue growth for 2025, with continued efforts to improve our earnings potential and leverage profile," said Todd Young, Executive Vice President and CFO of Elanco Animal Health. "As we navigate a dynamic macroeconomic backdrop, we remain confident in the underlying drivers of the 2025 outlook provided during the November earnings call. The only adjustment we have made is for incremental currency headwinds using rates from earlier this month. We expect 2025 adjusted EBITDA to be more back half weighted than our historical cadence, with the stronger dollar and as our strategic investments in global launches drive the expected ramp for innovation revenue contributions."